Trump Announces Nine More Pharma Deals; White House Projects $600 Billion in Savings

President Trump announced Monday that nine additional mid-size drugmakers have joined the administration’s Most Favored Nation pricing framework, bringing the total to 26 companies that the White House says cover 89 percent of the branded U.S. market. Speaking in the Oval Office with Health and Human Services Secretary Robert F. Kennedy Jr., CMS Administrator Mehmet Oz, and Commerce Secretary Howard Lutnick, Trump said the full package of agreements is projected to save Americans more than $600 billion. The Council of Economic Advisers estimate in the White House fact sheet is $600 billion over the next decade. Trump called the reductions “the largest drug discount, the largest price reductions in the history of medicine.” He said the remaining holdouts representing about 10 percent of the market “are also coming in. They have no choice.”

The nine companies named in the Aug. 31 fact sheet are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. They join 17 earlier signatories: Pfizer, AstraZeneca, EMD Serono, Eli Lilly, Novo Nordisk, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, Sanofi, Johnson & Johnson, AbbVie, and Regeneron. Under the new pacts, the companies agreed to sell outpatient drugs to state Medicaid programs at MFN prices—aligned with the lowest prices paid in other developed countries—and to launch future innovative medicines in the United States at those same international levels. State Medicaid participation is optional. The products cover glaucoma, hemophilia, liver disease, macular degeneration, Parkinson’s, skin conditions, and some cancers. TrumpRx, the administration’s direct-to-consumer site launched in February, is the cash-pay channel for discounted brand-name drugs; it does not process insurance claims. Teva said Monday it remains in active discussions to finalize its deal. BridgeBio said it would not disclose specifics, does not expect future pricing mandates, and that its commitment on new medicines is expected to exclude drugs approved solely for orphan indications. BeOne Medicines said it secured an exemption from Section 232 pharmaceutical tariffs. Prior MFN deals have included tariff relief; the White House did not publish full contract text for the nine.

The nine manufacturers committed to at least $19.6 billion in near-term U.S. manufacturing investment. Several also agreed to donate active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve: UCB, 163 tons of the anticonvulsant levetiracetam; Sun Pharma, 71.4 tons of clindamycin and 6.75 tons of doxycycline; Teva, 45 metric tons of metronidazole and 4.8 tons of the blood-pressure drug amlodipine; Astellas, 25 kilograms of the transplant immunosuppressant tacrolimus. The White House framed the stockpile donations as reducing reliance on foreign supply in an emergency. The Consumer Price Index showed pharmaceutical prices down 0.8 percent in July and 3.1 percent from a year earlier, the steepest annual decline in more than 60 years, according to figures cited with the announcement. Chris Klomp, HHS senior adviser and MFN negotiator, attributed the CPI drop to the pricing deals and TrumpRx. The first MFN pact was with Pfizer on Sept. 30, 2025, after letters to manufacturers in 2025. Trump said companies “make most of their money from the United States, meaning they’re ripping us off. But not any longer.” The administration presents the deals as voluntary agreements that peg U.S. launch and Medicaid prices to other developed nations rather than as statutory price controls. Remaining branded manufacturers have not signed.